Dihexa

Last updated: May 12, 2026. This page was originally published as a placeholder on April 24 and has been expanded with research and regulatory context. The full PeptidesBeat pillar guide for Dihexa will publish before the July 23-24 PCAC meeting.

Quick Summary

• What it is: Dihexa (also known as N-hexanoic-Tyr-Ile-Ahx-His(3-CH₂NH-cyclo(5-F₆-C₀₁)) amide) is a synthetic angiotensin IV analog developed for cognitive enhancement.
• Regulatory status: One of 12 therapeutic peptides reclassified by the FDA on April 15, 2026. Removed from Category 2 (significant safety concerns) into Category 1 (enforcement discretion). Final 503A Bulks List placement pending the July 23-24 PCAC meeting.
• Key research area: Preclinical studies suggest activity at the hepatocyte growth factor (HGF) receptor c-Met, with potential applications in synaptic plasticity and cognitive function.
• Human data: Very limited. Most available evidence comes from animal models and in vitro studies.

What Is Dihexa?

Dihexa is a synthetic peptide first described in the scientific literature by researchers studying angiotensin IV (AngIV) analogs. Unlike most therapeutic peptides discussed in the compounding policy context — which are typically derived from naturally occurring signaling molecules — Dihexa is a wholly synthetic construct designed to improve upon the pharmacokinetic properties of earlier AngIV-derived compounds.

The peptide was originally developed by researchers investigating the renin-angiotensin system’s role in cognitive function. Early AngIV analogs showed promise in animal models of memory and learning but suffered from poor metabolic stability. Dihexa was designed with structural modifications — including a hexanoic acid tail and a reduced peptide bond — intended to improve its resistance to enzymatic degradation and blood-brain barrier penetration.

Research Status

Preclinical Evidence

The majority of published research on Dihexa comes from the laboratory of Dr. Joseph W. Harding and colleagues at Washington State University, who hold several patents related to the compound. Key findings from this body of work include:

• Memory enhancement: Animal studies have reported that Dihexa administration improves performance in the Morris water maze and other spatial learning tasks.
• Synaptic plasticity: The compound has been shown to increase dendritic spine density in hippocampal neurons in vitro, suggesting a potential mechanism for its reported cognitive effects.
• c-Met receptor activity: Dihexa is believed to act as a positive modulator of the hepatocyte growth factor (HGF) receptor c-Met, a signaling pathway involved in neuronal survival and synaptic function.

Human Clinical Data

Published human data on Dihexa is extremely limited. As of May 2026, no large-scale, peer-reviewed clinical trials examining Dihexa’s safety or efficacy in humans have been published in indexed medical journals. This places Dihexa among the least clinically characterized of the 12 peptides reclassified by the FDA on April 15.

The gap between preclinical promise and clinical evidence is particularly wide for Dihexa compared to compounds like BPC-157 or GHK-Cu, which have more substantial human safety records. This lack of human data is a significant consideration for regulatory decision-making and for clinicians evaluating whether to prescribe the compound.

Regulatory Status

April 15, 2026 Reclassification

The FDA’s April 15, 2026 action removed Dihexa from the 503A “demonstrably difficult to compound” list (previously Category 2) and placed it into Category 1 (enforcement discretion). This action cleared the legal compounding path for the compound under valid prescriptions through licensed 503A pharmacies.

Important distinction: Unlike GHK-Cu, which was listed in Category 1 from the start of the April 15 action, Dihexa was initially among the 12 peptides targeted for reclassification. Its current Category 1 placement means the FDA will exercise enforcement discretion regarding its compounding, but the agency has not made a final determination about its placement on the 503A Bulks List.

Pre-PCAC Status

The final 503A Bulks List placement for Dihexa — and the other Category 1 and Category 2 compounds — is pending the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting. The PCAC will review whether the available evidence supports permanent placement on the bulks list, which would codify the compound’s legal status for compounding purposes.

Notably, Dihexa is not among the seven Category 2 peptides scheduled for presentation at the July PCAC meeting. Those seven — BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax — face a more contested regulatory path because they were placed in Category 2 (significant safety concerns). Dihexa’s Category 1 placement suggests a lower regulatory risk profile, but the PCAC could still recommend changes to its status.

What This Means for Prescribers and Patients

For clinicians and patients considering Dihexa, the regulatory landscape has improved substantially since the April 15 reclassification, but significant uncertainties remain:

1. Legal access: Licensed prescribers can now prescribe Dihexa through PCAB-accredited compounding pharmacies under valid patient prescriptions, subject to state pharmacy board rules.
2. Evidence gap: The limited human safety data means that prescribing decisions should be made with careful informed consent.
3. Regulatory uncertainty: The July PCAC meeting could adjust Dihexa’s status. Any change would affect prescribing and compounding access.

Standard clinical precautions apply: work with a licensed prescriber qualified to evaluate whether the compound is appropriate; source through accredited compounding pharmacies, not the research-chemical channel; and verify state-specific pharmacy board rules.

Future Outlook

PeptidesBeat will update this guide as new research emerges and as the July PCAC meeting clarifies Dihexa’s long-term regulatory status. Subscribe to the PeptidesBeat newsletter for alerts when significant developments occur.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.